Testimonials

Olivier Lacombe
Olivier Lacombe
Head of Pharmacokinetics - Inventiva
Inventiva and PhinC have been collaborating for several years on popPK and PBPK modeling activities. The decision to work with PhinC was based on the team expertise in pharmacokinetics and modeling within drug development, and their aptitude to react and to collaborate within a biotech context. Moreover their approach is based on the client listening and project understanding in order to propose the most adequate proposal to the request. Our relationship is very pleasant, efficient and fruitful for both the scientific and project outputs.
Agnes Hemon
Agnes Hemon
Preclinical and P.K clinical Officer - HRA Pharma
PhinC is one of HRA Pharma’s valuable partners for pharmacokinetic studies. From just an advice to modelling, we know we can trust them to efficiently support and carry out our projects.
Antoine Tarral
Antoine Tarral
Head of HAT Clinical Programme - DNDi
The PhinC Development team has accompanied us throughout this program. In particular, their expertise in pharmacokinetic modeling has enabled us to select the therapeutic dose and optimize the dose regimen. I most particularly appreciated their continuous involvement, their professionalism and their ability to work together with all the other actors involved in this program.
John DiBella
John DiBella
President, Lancaster Division - Simulations Plus, Inc. (NASDAQ: SLP)
Simulations Plus has formed a strong relationship with PhinC as we work together to drive increased adoption of physiologically-based pharmacokinetic (PBPK) modeling to support pharmaceutical research and development. Their talented team of scientists have become proficient users of our GastroPlus™ software platform, and we are confident that the services they provide to clients are valuable and greatly impact R&D productivity.
Club Phase 1
GMP - Groupe de Métabolisme et Pharmacocinétique
EUFEMED
AFSSI